How to appeal a Highmark bph procedures + medical therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for bph procedures + medical therapy

Cited policy: BCBS Medical Policy: Prostatic Artery Embolization (PAE) for BPH

LUTS attributed to BPH refractory to medical therapy AND patient is high surgical risk OR refuses transurethral surgery. Prostate volume typically >40 cc. Performed by interventional radiologist with prostatic-artery embolization experience.

How Highmark denies bph procedures + medical therapy — and how to counter it

Where Highmark pushes back: 1) Experimental / investigational; 2) Insufficient long-term outcome data; 3) Must trial transurethral surgery first; 4) Not standard of care.

Counter-arguments that hold up: AUA BPH 2018 + 2023 amendment (Sep 2023) provide CONDITIONAL recommendation for PAE in high-surgical-risk patients unable to tolerate transurethral surgery. PARTEM RCT and Pisco / Bilhim European data support. SIR (Society of Interventional Radiology) endorses. Submit ASA class, anesthesia consult declining GA, anticoagulation history. CPT 37243. Document why TURP / HoLEP / Aquablation contraindicated.

What Highmark typically denies for bph procedures + medical therapy

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For bph procedures + medical therapy, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the bph procedures + medical therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• UroLift
• Rezum
• Aquablation
• iTind
• Optilume BPH
• GreenLight PVP

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.